Migraine is a significant global health issue, particularly in low and middle-income countries where access to diagnosis and treatment is limited. Despite recent advancements in migraine research, including new preventative medications targeting the CGRP pathway, the burden of migraine remains largely underrepresented in these regions. The economic impact is staggering, with indirect costs potentially reaching 2% of GDP annually due to migraine-related disabilities.
